|
1
|
Yu Y, Xu X, Du Z and Shi M: Non-platinum
regimens of gemcitabine plus docetaxel versus platinum-based
regimens in first-line treatment of advanced non-small cell lung
cancer: a meta-analysis on 9 randomized controlled trials. Cancer
Chemother Pharmacol. 69:1265–1275. 2012.
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, et al; West Japan Oncology Group. Gefitinib
versus cisplatin plus docetaxel in patients with non-small-cell
lung cancer harbouring mutations of the epidermal growth factor
receptor (WJTOG3405): an open label, randomised phase 3 trial.
Lancet Oncol. 11:121–128. 2010.
|
|
3
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, et al; North-East Japan Study Group.
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Eng J Med. 362:2380–2388. 2010.
|
|
4
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, et al: Gefitinib or carboplatin-paclitaxel in
pulmonary adenocarcinoma. N Eng J Med. 361:947–957. 2009.
|
|
5
|
Gridelli C, Butts C, Ciardiello F, Feld R,
Gallo C and Perrone F: An international, multicenter, randomized
phase III study of first-line erlotinib followed by second-line
cisplatin/gemcitabine versus first-line cisplatin/gemcitabine
followed by second-line erlotinib in advanced non-small-cell lung
cancer: treatment rationale and protocol dynamics of the TORCH
trial. Clin Lung Cancer. 9:235–238. 2008.
|
|
6
|
Thatcher N, Chang A, Parikh P, Rodrigues
Pereira J, Ciuleanu T, von Pawel J, et al: Gefitinib plus best
supportive care in previously treated patients with refractory
advanced non-small-cell lung cancer: results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005.
|
|
7
|
Maruyama R, Nishiwaki Y, Tamura T,
Yamamoto N, Tsuboi M, Nakagawa K, et al: Phase III study, V-15-32,
of gefitinib versus docetaxel in previously treated Japanese
patients with non-small-cell lung cancer. J Clin Oncol.
26:4244–4252. 2008.
|
|
8
|
Ebi N, Semba H, Tokunaga SJ, Takayama K,
Wataya H, Kuraki T, et al; Lung Oncology Group in Kyushu, Japan. A
phase II trial of gefitinib monotherapy in chemotherapy naïve
patients of 75 years or older with advanced non-small cell lung
cancer. J Thorac Oncol. 3:1166–1171. 2008.
|
|
9
|
Zhou H, Zeng C, Wang LY, Xie H, Zhou J,
Diao P, et al: Chemotherapy with or without gefitinib in patients
with advanced non-small-cell lung cancer: a meta-analysis of 6,844
patients. Chin Med J (Engl). 126:3348–3355. 2013.
|
|
10
|
Petrelli F, Borgonovo K, Cabiddu M, Lonati
V and Barni S: Relationship between skin rash and outcome in
non-small-cell lung cancer patients treated with anti-EGFR tyrosine
kinase inhibitors: a literature-based meta-analysis of 24 trials.
Lung Cancer. 78:8–15. 2012.
|
|
11
|
Schumann C, Heigener D, Dittrich I, et al:
Long term benefit from erlotinib treatment is independent of
prognostic factors and therapeutic response (abstract 9146). Eur J
Cancer. 7:12009.
|
|
12
|
Kaira K, Takahashi T, Murakami H, Tsuya A,
Nakamura Y, Naito T, et al: Long-term survivors of more than 5
years in advanced non-small cell lung cancer. Lung Cancer.
67:120–123. 2010.
|
|
13
|
Nakatomi K, Soda H, Kitazaki T, Nakano H,
Uchida K, Urabe S, et al: Long-term survival in three patients with
metastatic non-small cell lung cancer treated with gefitinib. Lung
Cancer. 52:253–255. 2006.
|
